A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age50+
SponsorVasa Therapeutics
About this trial
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
Eligibility criteria
Qualifiers
Males or females ≥ 50 years of age at the time of signing the informed consent.
Diagnosis of HFpEF as defined by European Society of Cardiology or American College of Cardiology/American Heart Association criteria
NYHA Functional Class II or III
LVEF ≥ 50% demonstrated by echocardiography (ECHO) performed at Screening with evidence of heart failure
Disqualifiers
Female trial participant who is pregnant or breastfeeding.
Known hypersensitivity to VS-041.
Cardiovascular disease other than HFpEF
Active intercurrent illness such as acute bacterial or viral infection.
Trial design
Treatments tested in this trial
- VS-041
- Placebo
Treatment groups
42 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov